Bolt Biotherapeutics Delisted from Nasdaq

Ticker: BOLT · Form: 8-K · Filed: Jun 6, 2025 · CIK: 1641281

Bolt Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyBolt Biotherapeutics, Inc. (BOLT)
Form Type8-K
Filed DateJun 6, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, corporate-governance

TL;DR

Bolt Biotherapeutics got kicked off Nasdaq, filing 8-K on 6/6/25.

AI Summary

Bolt Biotherapeutics, Inc. filed an 8-K on June 6, 2025, to report its delisting from the Nasdaq Capital Market due to failure to meet continued listing standards. The company also amended its Articles of Incorporation and Bylaws. Bolt Biotherapeutics, Inc. was formerly known as Bolt Therapeutics, Inc. and changed its name on May 4, 2015.

Why It Matters

This filing indicates that Bolt Biotherapeutics is no longer listed on a major stock exchange, which can significantly impact its ability to raise capital and its stock's liquidity.

Risk Assessment

Risk Level: high — Delisting from a major exchange like Nasdaq is a significant negative event that severely impacts a company's financial standing and investor confidence.

Key Players & Entities

  • Bolt Biotherapeutics, Inc. (company) — Registrant
  • Nasdaq Capital Market (company) — Exchange from which delisted
  • June 6, 2025 (date) — Date of filing and delisting event
  • Bolt Therapeutics, Inc. (company) — Former company name
  • May 4, 2015 (date) — Date of name change

FAQ

What is the primary reason for Bolt Biotherapeutics' 8-K filing on June 6, 2025?

The primary reason is the company's delisting from the Nasdaq Capital Market due to failure to satisfy continued listing standards.

What other corporate actions are reported in this 8-K filing?

The filing also reports amendments to the company's Articles of Incorporation and Bylaws.

When did Bolt Biotherapeutics change its name?

Bolt Biotherapeutics, Inc. changed its name from Bolt Therapeutics, Inc. on May 4, 2015.

What is the principal executive office address for Bolt Biotherapeutics, Inc.?

The principal executive offices are located at 900 Chesapeake Drive, Redwood City, California 94063.

What is the Commission File Number for Bolt Biotherapeutics, Inc.?

The Commission File Number for Bolt Biotherapeutics, Inc. is 001-39988.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 6, 2025 regarding Bolt Biotherapeutics, Inc. (BOLT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.